Clinical study on the risk of sarcopenia in patients with advanced lung cancer undergoing anti-tumor therapy
Objective To analyze the influencing factors of sarcopenia in patients with advanced lung cancer undergoing anti-tumor therapy,and to explore the adverse effects of sarcopenia on patients with ad-vanced lung cancer undergoing anti-tumor therapy.Methods Patients with advanced lung cancer who received anti-tumor therapy in the Department of Oncology of a tertiary hospital in Chengdu from January to December 2021 were continuously included.The incidence situation of sarcopenia in patients with advanced lung cancer undergoing anti-tumor therapy was evaluated by using the 12th thoracic spine (T12) skeletal muscle index (SMI) standard.According to the diagnostic criteria of sarcopenia,the patients were divided into the sarcope-nia group and the non-sarcopenia group.Multivariate logistic regression was used to analyze the influencing factors of sarcopenia in patients with advanced lung cancer undergoing anti-tumor therapy.Results A total of 285 patients were included in this study,of which 123 cases (43.15％) were diagnosed as sarcopenia.Multiva-riate analysis showed that gender (P<0.001),pathological stage (P=0.012),creatinine (P=0.031) and BMI (P<0.001) were the influencing factors of sarcopenia in patients with advanced lung cancer undergoing anti-tumor therapy.The quality of life score of patients in the sarcopenia group was significantly lower than that in the non-sarcopenia group (P=0.035).Conclusion The incidence of sarcopenia in patients with ad-vanced lung cancer undergoing anti-tumor therapy is high,which is related to many factors and affects the quality of life.
sarcopeniaadvanced lung cancerrelated factorsquality of life
万方数据
维普
